| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Two days after administration of (14)C-labeled methyl palmitate via gastric tube, the retention and distribution of (14)C activity in tissue lipids and fatty acids were determined. Low retention was observed in adipose-deficient young rats. Retention was detected in brain tissue after 17 days. The highest activity levels were detected in cadaveric rats. Biological Half-Life Following administration of methyl palmitate via gastric tube to rats, the utilization of 14C-labeled palmitic acid in their exhaled breath was determined. Labeled carbon dioxide excretion showed two consecutive peaks at 3 and 18 hours. The administered amount of palmitic acid was only half of the first peak. These two consecutive peaks indicate fatty acid recycling in the rats. The half-life of labeled palmitic acid was 3 hours. |
|---|---|
| Toxicity/Toxicokinetics |
Interactions
Methylpalmitate is an inhibitor of reticuloendothelial system (RES) function. When administered to dextran-treated mice, it both inhibits RES function and leads to elevated serum lysozyme levels. In endotoxin-sensitive dextran-treated rats, administration of methylpalmitate (a reticuloendothelial inhibitor that confers endotoxin resistance) followed by treatment with Salmonella enteritidis endotoxin resulted in elevated plasma aspartate aminotransferase (AST) and hypoglycemia. The reduction in chromium-labeled erythrocytes in incompatible sheep vascular clearance and organ uptake mice was attributed to impaired phagocytosis in the liver and spleen following injection of the reticuloendothelial system inhibitor methylpalmitate, leading to decreased vascular clearance. Intravenous injection of 100 mg/100 g methylpalmitate into rats improved survival rates at endotoxin doses ranging from 0.75 to 3.0 mg/100 g. Although intravenous injection of 0.5 mg/100 g Salmonella endotoxin into normal rats resulted in an average mortality rate of 38%, a 6-fold increase in dose did not lead to death. Methyl palmitate group: When dextran-treated rats were administered methyl palmitate, normal phagocytic activity was induced in the presence of reticuloendothelial system hypertrophy. For more complete data on interactions of methyl palmitate (8 in total), please visit the HSDB records page. |
| References |
|
| Additional Infomation |
Methyl palmitate is a fatty acid methyl ester and a metabolic product. It has been reported to be found in tea plants, Peperomia speciosa, and other organisms with relevant data.
|
| Molecular Formula |
C17H34O2
|
|---|---|
| Molecular Weight |
270.4507
|
| Exact Mass |
270.255
|
| CAS # |
112-39-0
|
| Related CAS # |
Methyl palmitate-13C16;Methyl palmitate-d31;29848-79-1
|
| PubChem CID |
8181
|
| Appearance |
Colorless to white solid-liquid Mixture
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
332.1±0.0 °C at 760 mmHg
|
| Melting Point |
32-35 °C(lit.)
|
| Flash Point |
152.8±7.5 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.441
|
| LogP |
7.62
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
19
|
| Complexity |
190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
FLIACVVOZYBSBS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H34O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(18)19-2/h3-16H2,1-2H3
|
| Chemical Name |
methyl hexadecanoate
|
| Synonyms |
Methyl hexadecanoate; Palmitic acid methyl ester; Hexadecanoic acid, methyl ester; Palmitic acid, methyl ester; Methyl n-hexadecanoate; Uniphat A60
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~50 mg/mL (~184.88 mM)
DMSO : ~50 mg/mL (~184.88 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (92.44 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 250.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 30 mg/mL (110.93 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6975 mL | 18.4877 mL | 36.9754 mL | |
| 5 mM | 0.7395 mL | 3.6975 mL | 7.3951 mL | |
| 10 mM | 0.3698 mL | 1.8488 mL | 3.6975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
